CSLCSLLY -0.30%73 Forward PE Ratio is 12.19 as of Jun. 30, 2026. GuruFocus rates CSLLY with a GF Score™ of 73/100 and a GF Value™ of $48.70 (Significantly Undervalued). The stock has 7 warning signs investors should review. Among 355 Biotechnology companies, CSL ranks better than 67.04% on this metric.
The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.
Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .
CSL Forward PE Ratio Related Terms
CSL Forward PE Ratio Historical Data
* Premium members only.
The historical data trend for CSL's Forward PE Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CSL Forward PE Ratio Chart
CSL Annual Data
Trend
2016-06
2017-06
2018-06
2019-06
2020-06
2021-06
2022-06
2023-06
2024-06
2025-06
Forward PE Ratio
22.22
26.88
33.22
32.68
39.84
43.86
40.49
33.44
27.93
21.43
CSL Semi-Annual Data
2015-12
2016-06
2016-12
2017-06
2017-12
2018-06
2018-12
2019-06
2019-12
2020-06
2020-12
2021-06
2021-12
2022-06
2022-12
2023-06
2023-12
2024-06
2025-06
2025-12
Forward PE Ratio
26.53
22.22
26.67
26.88
31.06
33.22
31.35
32.68
40.32
39.84
42.19
43.86
45.05
40.49
41.84
33.44
27.55
27.93
21.43
17.29
CSLLY vs VRTX, REGN, ALNY: Forward PE Ratio Comparison
For the Biotechnology subindustry, CSL's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CSL Forward PE Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, CSL's Forward PE Ratio distribution charts can be found below:
* The bar in red indicates where CSL's Forward PE Ratio falls into.
It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.
CSL (CSLLY) has a Forward PE Ratio of 12.19 as of Jun. 30, 2026. Forward P/E ratio is the share price dividend by the expected per-share earnings in the next 12 months. View historical data on CSL and its competitors. According to the industry distribution chart, CSL ranks #117 out of 355 companies in the Biotechnology industry, placing it in the top 33%.
Is CSL's Forward PE Ratio too high?
CSL's current Forward PE Ratio is 12.19. The Biotechnology industry median Forward PE Ratio is 22.34. CSL's value of 12.19 is 45.4% below this industry median. Based on the distribution chart, CSL ranks #117 out of 355 companies in the Biotechnology industry, which is above the industry midpoint. Overall, CSL has a GF Score™ of 73/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does CSL's Forward PE Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, CSL ranks #117 out of 355 companies for Forward PE Ratio. This puts CSL in the upper half of its industry. The industry median Forward PE Ratio is 22.34. CSL's value of 12.19 is 45.4% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Forward PE Ratio for a Biotechnology company?
The median Forward PE Ratio among Biotechnology companies is 22.34, based on 355 companies in the industry. Companies in the top quartile (top 25%) have a Forward PE Ratio significantly above this median, while those in the bottom quartile fall well below. However, Forward PE Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. CSL's current Forward PE Ratio of 12.19 is 45.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Forward PE Ratio mean?
A high Forward PE Ratio can signal that a stock is expensive relative to its fundamentals. Forward P/E ratio is the share price dividend by the expected per-share earnings in the next 12 months. View historical data on CSL and its competitors. For the Biotechnology industry, the median Forward PE Ratio is 22.34 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. CSL's current Forward PE Ratio is 12.19. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CSL stock overvalued right now?
Based on GuruFocus' analysis, CSL (CSLLY) is currently considered Significantly Undervalued. The stock's GF Value™ is $48.70, compared to a current price of $20.06 — trading 58.8% below its estimated fair value. The current Forward PE Ratio is 12.19 and 45.4% below the Biotechnology industry median of 22.34. CSL's overall GF Score™ is 73/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Forward PE Ratio calculated?
Forward PE Ratio is calculated from a company's financial statements. For CSL (CSLLY), the current Forward PE Ratio is 12.19 as of Jun. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is CSL (CSLLY) Overvalued in 2026?
Based on GuruFocus' analysis, CSL stock appears to be undervalued.
The current stock price of $20.06 is trading 58.8% below its estimated GF Value™ of $48.70.
GuruFocus considers CSL to be Significantly Undervalued.
Key valuation signals for CSLLY:
Forward PE Ratio: 12.19
GF Value™: $48.70 vs. price of $20.06 (58.8% below fair value)
Industry Position: 45.4% below the Biotechnology median (#117 of 355)
No single metric tells the full story. See the CSLLY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
CSL is one of the largest global biotech companies and has three main segments. CSL Behring either uses plasma-derived proteins or recombinants to treat conditions including immunodeficiencies, bleeding disorders, and neurological indications. CSL Seqirus is the world's second-largest influenza vaccination business and was acquired in fiscal 2016. CSL Vifor is an iron deficiency and nephrology business and was acquired in fiscal 2023. CSL has a strong R&D track record, and the product portfolio and pipeline include nonplasma products as the firm continues to broaden its scope. Originally formed in Australia as a government-owned entity, CSL now earns roughly half its revenue in North America and a quarter in Europe.
73GF Score
Get the complete analysis for CSLLY
Forward PE Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CSLLY has been successfully added to your 